X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VLA1601 is a highly purified inactivated zika virus vaccine candidate adsorbed on alum, which is being evaluated for the treatment of zika virus infection.
Lead Product(s): VLA1601
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1601
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Valneva sold its tropical disease PRV for FDA approved of Ixchiq, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $103.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 05, 2024
Details:
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV). It is being evaluated in phase 2 clinical trials evaluating the safety and Immunogenicity in children,
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
VLA15, an alum-adjuvanted formulation administered intramuscularly, is a vaccine candidate currently undergoing clinical development. It is in Phase III clinical trial studies for the treatment of Lyme disease.
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA15
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus which was recently approved by USFDA. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus and company believes the regulatory review could be completed by mid-2024.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Lead Product(s): Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ixchiq
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
